Drug intelligence / Profile preview

Meningococcal (groups A and C) polysaccharide vaccine

Development stage
Unknown
Lead developer
Parent
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

Meningococcal (groups A and C) polysaccharide vaccine is a bivalent, non-conjugated bacterial vaccine composed of purified capsular polysaccharides from *Neisseria meningitidis* serogroups A and C. It works by inducing the production of antibodies against these specific serogroups, providing active immunization to prevent invasive diseases such as meningitis and septicemia caused by *Neisseria meningitidis*. The mechanism of action involves stimulating an immune response specifically targeting the bacterial capsule. This type of plain (non-conjugate) polysaccharide vaccine does not generate long-term immune memory but provides short-term protection with high efficacy in older children and adults. The first versions were developed in the 1970s for use among military recruits in response to epidemics[6]. These vaccines have been largely replaced or supplemented by conjugate vaccines due to improved immunogenicity in young children[5][6].

Other names
meningococcal A and C polysaccharide vaccinebivalent meningococcal polysaccharide vaccine
02

Targets

NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharide

Beyond the preview

Go deeper on Meningococcal (groups A and C) polysaccharide vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meningococcal (groups A and C) polysaccharide vaccine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call